PT  - JOURNAL ARTICLE
AU  - Danion, François
AU  - Letscher-Bru, Valérie
AU  - Guitard, Juliette
AU  - Sitbon, Karine
AU  - Dellière, Sarah
AU  - Angoulvant, Adela
AU  - Desoubeaux, Guillaume
AU  - Botterel, Francoise
AU  - Bellanger, Anne-Pauline
AU  - Gargala, Gilles
AU  - Uhel, Fabrice
AU  - Bougnoux, Marie-Elisabeth
AU  - Gerber, Victor
AU  - Michel, Justin
AU  - Cornu, Marjorie
AU  - Bretagne, Stéphane
AU  - Lanternier, Fanny
AU - the COVID-Mucor study group
TI  - High mortality of COVID-19 associated mucormycosis in France: a nationwide retrospective study
AID  - 10.1101/2021.07.05.21260041
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.07.05.21260041
4099  - http://medrxiv.org/content/early/2021/07/07/2021.07.05.21260041.short
4100  - http://medrxiv.org/content/early/2021/07/07/2021.07.05.21260041.full
AB  - We studied COVID-19 associated mucormycosis based on 17 cases reported nationwide and assessed the differences with India. They differed by frequencies of diabetes mellitus (47% in France versus 95% in India), hematological malignancies (35% versus 1%), anatomical sites (53% lung versus >80% rhino-orbito-cerebral) and prognosis (>80% mortality versus <50%).Competing Interest StatementFD declares personal fees from Gilead outside the submitted work. FL declares personal fees from Gilead and F2G outside the submitted work. Other Authors have nothing to declare.Funding StatementNo fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study is part of the NRCMA official duties which are approved by the Institut Pasteur Internal Review Board (2009-34/IRB) in accordance with French Law.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available on request from the corresponding author